Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Exchangeable-template-reaction

 Strategically modified hepatitis B core proteins and their derivatives
The present invention relates to a strategically modified hepatitis B core (HBc) protein that is ...


 Chimeric biotin-binding papillomavirus protein
OF THE INVENTION The first domain of the chimeric protein includes at least a portion of a ...


 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
OF THE INVENTION DEFINITIONS As used in this application, the following words or phrases have the ...


 MYPPPY variants of CTL A4 and uses thereof
OF THE INVENTION Definition As used in this application, the following words or phrases have the ...


 CTLA4 receptor and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the ...


 CTLA4/CD28Ig hybrid fusion proteins and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the ...


 Method of regulating cellular processes mediated by B7 and CD28
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 ...


 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
This invention is based, at least in part, on the discovery of novel ligands which bind a T cell ...


 Method for generating and identifying antibodies directed against a B7
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 ...


 Polypeptide that interacts with heat shock proteins
Described herein are the isolation and characterization of a polypeptide, particularly a ...


 Exchangeable template reaction

Details
Inventors: Khudyakov, Yury; Fields, Howard A.;
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Primary Examiner: Jones; W. Gary
Assistant Examiner: Myers; Carla
Attorney, Agent or Firm: Needle & Rosenberg

The invention provides a method for the synthesis of DNA based on a cyclic mechanism of combining deoxyoligonucleotides comprising combining: (a) a series of unique single-stranded deoxypolynucleotides, each having a 5' sequence which, when in double-stranded form, can be enzymatically treated to form a unique 3' single-stranded protrusion for selective cyclic hybridization with another unique single-stranded deoxypolynucleotide of the series; (b) a unique deoxypolynucleotide having a 3' sequence which can selectively hybridize with one of the unique single-stranded deoxypolynucleotides of (a); (c) a polymerase which can direct the formation of double-stranded deoxypolynucleotides from the single-stranded deoxypolynucleotides; and (d) an enzyme which can form a unique single-stranded 3' protrusion from the double-stranded deoxypolynucleotides; under conditions which hybridize the unique single-stranded deoxypolynucleotides in a cyclic manner to form the DNA. Also provided is a kit comprising a series of unique synthesized single-stranded deoxypolynucleotides, each having a 5' sequence which, when in double-stranded form, can be enzymatically treated to form a unique 3' single-stranded protrusion for selective cyclic hybridization with another unique single-stranded deoxypolynucleotide of the series.

DETAILED DESCRIPTION OF THE INVENTION Description of the Exchangeable Template Reaction (ETR) mechanism.
The ETR is a method for the synthesis of long polynucleotide DNA fragments using short synthetic oligonucleotides as templates for DNA polymerase.
The method is based on a cyclic mechanism involving three main components: (1) polymerase activity to synthesize double-stranded DNA, (2) enzymatic activity to create 3' terminal single-stranded regions, and (3) specifically designed synthetic deoxyoligonucleotides used as templates for the polymerase reaction.
The critical step is the enzymatic creation of a 3' terminal single-stranded region at the "growing point" of the synthesizing polynucleotide chain, which is used for the complementary binding of the next oligonucleotide as a template to continue the polymerase reaction.
The order of oligonucleotide additions for each cycle is encoded in each 3' terminal sequence.
At the 3' terminus of the growing DNA molecule a specific sequence of nucleotides can anneal with a complementary sequence of nucleotides from the synthetic oligonucleotide.
Thus, it is possible to synthesize a long DNA fragment in one step by simply combining the entire set of deoxyoligonucleotides in one reaction tube containing all the required enzymatic activities and incubating the mixture at the optimal temperature and optimal buffer.
Each cycle begins with the complementary binding of the 3' terminal region of a synthetic oligonucleotide with the 3' protruding region of double-stranded DNA (step 1 in FIG.
1).
After annealing, a DNA polymerase reaction occurs to create a second strand of DNA using the short synthetic oligonucleotide as a template for DNA polymerase (step 2 in FIG.
1).
After polymerization is complete, the double-stranded DNA has been extended by the length of the synthetic oligonucleotide.
To initiate the second round in the cycle of DNA synthesis, another enzymatic reaction occurs that creates a 3' protruding single-stranded region by removing several nucleotides from the 5' terminus leaving a 3' protrusion



Related patents
  Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
  Transgenic non-human animals capable of producing heterologous antibodies
The design of a transgenic non-human animal that responds to foreign antigen stimulation with a heterologous antibody repertoire, requires that the heterologous ...
  Transgenic non-human animals capable of producing heterologous antibodies
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
  Transgenic non-human animals for producing heterologous antibodies
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
  Nucleic acids encoding lymphoid CD30 antigen
We claim: 1. An isolated nucleic acid molecule comprising a polynucleotide having a sequence encoding the amino acid sequence of SEQ. ID. NO.: 2. 2. A recombinant vector ...
  Feeding tray for multiwell test apparatus
This invention will be described herein with reference to the growing and use of cells on a membrane positioned and secured to the bottom of each of a multiplicity of ...
  Neo-tryptophan
What is claimed is: 1. A method of making a neurotensin polypeptide containing neo-tryptophan, said method comprising: a) providing a neo-tryptophan derivative, and b) ...
  Human immunodeficiency virus decoy
OF THE INVENTION The present invention has wide application to immunologic procedures and methods wherein antigenic material or other biologically active moieties are ...
  Capsid forming and cystein modified chimaeric MS2-coat protein
We claim: 1. A modified coat protein capable of forming a capsid which comprises the coat protein of a bacteriophage selected from the group consisting of MS-2, R17 and ...
  Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
This invention relates to the discovery of an anti-idiotype antibody that is capable of recruiting a tumor-specific response against GD2. The antibody is designated 1A7....

0.034

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved